NK cell therapy with two immune agents for returning lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of specially grown immune cells (NK cells) plus two drugs that help them attack cancer. It's for people with a type of B-cell lymphoma that came back after at least two prior treatments or a stem cell transplant, and who have either failed or are not eligible for CAR-T cell therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have diffuse large B-cell or follicular lymphoma that came back or didn't respond to at least 2 prior treatments or a stem cell transplant.
- You either had CAR-T therapy that didn't work or you are not able to get CAR-T cells.
- Your tumor has a marker called CD19 or CD20 (a test from a biopsy).
- You are between 18 and 80 years old.
- Your kidneys, liver, lungs, and heart are working well enough (doctors will check).
- You are not pregnant or breastfeeding, and if you are able to have children, you agree to use very effective birth control during and for some time after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment using natural killer (NK) cells that are specially created in the lab to find and attack cancer cells that have a protein called CD5 on their surface. The treatment is given along with chemotherapy to help the NK cells work better. It may be an option for people with certain types of T-cell lymphoma or leukemia that have not responded to other treatments.
This trial tests a new type of cell therapy called CAR NK cells that are designed to find and attack lymphoma cells carrying a marker called CD70. It is for people whose lymphoma either did not go away after the first treatment or came back within a year.
This trial tests a new treatment using natural killer (NK) cells, a type of immune cell, to fight advanced solid tumors. It may be an option if standard treatments have stopped working or are not available.
This trial tests a new type of immune cell therapy (NK cells) for patients with malignant brain tumors that have come back or worsened despite previous treatment. The goal is to see if these specially prepared immune cells can help fight the cancer.
This trial tests a new type of immune cell therapy (CIML NK cells) given directly into the abdomen for women with ovarian cancer that has come back and is now resistant to standard platinum chemotherapy. The goal is to see if these specially trained cells can fight the cancer safely.
This study tests whether adding your own natural killer (nk) cells (a type of immune cell) to your regular treatment helps fight non-hodgkin lymphoma that has come back or not responded. The goal is to see if this extra treatment is safe and works better at stopping the cancer.
Hear when a new Recurrent B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.